预约演示
更新于：2025-06-17
Tiotropium Bromide
噻托溴铵
更新于：2025-06-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 英国 (2002-04-02), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H24BrNO5S2 |
InChIKeyMQLXPRBEAHBZTK-SEINRUQRSA-M |
CAS号411207-31-3 |
关联
368
项与 噻托溴铵 相关的临床试验CTR20250492
评估受试制剂噻托溴铵吸入喷雾剂与参比制剂噻托溴铵吸入喷雾剂（思力华®能倍乐®）作用于健康成年受试者的单中心、开放、随机、单剂量、交叉生物等效性研究
NCT06679465
Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
CTR20244439
噻托溴铵吸入粉雾剂在中国成年健康受试者中的一项随机、开放、空腹单次给药、两制剂、两周期交叉的生物等效性试验
100 项与 噻托溴铵 相关的临床结果
登录后查看更多信息
100 项与 噻托溴铵 相关的转化医学
登录后查看更多信息
100 项与 噻托溴铵 相关的专利（医药）
登录后查看更多信息
2,365
项与 噻托溴铵 相关的文献（医药）2025-07-01Drug Delivery and Translational Research
Dendrimer-mediated proton sponge effect in the treatment of pulmonary acidosis
Article
作者: Borse, Kadambari ; Shende, Pravin
The present study aimed to synthesize tiotropium bromide (TIO)-loaded generation 5 polyamidoamine dendrimers (TIO-PAMAM-G5-DMs) using a solvent-free microwave assisted synthesis (MAS) for the treatment of pulmonary acidosis, a condition associated with decreased blood pH due to bronchoconstriction. The encapsulation of TIO into PAMAM-G5-DMs was achieved using MAS Michael addition and amidation reactions, following green chemistry principles. The DMs demonstrated particle size of 460.68 ± 1.38 nm, entrapment efficiency of 92.4 ± 0.44%, controlled release profiles of 90.4 ± 0.62% and 76 ± 0.84% in media of pH 6.8 and 7.4, respectively, and high buffering capacity (25 mL/pH units) using a proton sponge effect for the release of the drug into the system as compared to the conventional formulation. A synergistic rat model was used to compare the pharmacokinetics (PK) of marketed and DM-based formulations. The results showed a mean Cmax of 1987 ng/mL, tmax of 6 h, AUC of 10013863.5 ng.h/mL, and t½ of 18.59 h, respectively. The DMs exhibited low cytotoxicity, good biocompatibility, and higher IC50 value (> 10 µg) on human lung epithelial cell line BEAS-2B. Thus, our study introduces a cutting-edge alternative approach for treating pulmonary acidosis using PAMAM-DMs with proton sponge effect.
2025-06-01Pulmonary Therapy
A Brief Report on a Systematic Review of Real-World Effectiveness Studies of ICS/LAMA/LABA for Treatment of Adults with Asthma in the US
Review
作者: Paczkowski, Rosirene ; Noorduyn, Stephen G ; Forero-Schwanhaeuser, Sergio ; Moore, Alison ; Martin, Amber ; Schaible, Kassandra ; Begaj, Kejsi
INTRODUCTION:
Long-acting muscarinic antagonist (LAMA) addition to inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) dual therapy is recommended for severe asthma, but its real-world effectiveness is not well established.
METHODS:
A systematic literature review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to investigate clinical outcomes in US adults with asthma receiving ICS + LABA + LAMA as multiple-/single-inhaler triple therapy (MITT/SITT). Real-world/observational studies published in English in Embase/MEDLINE databases (2014-2024) and conference abstracts presented 2022-2024 were eligible for inclusion.
RESULTS:
From 588 identified records, only 8 articles reporting 6 unique studies were included; 2 assessed SITT and 4 assessed MITT, and 4 treatments were investigated. Exacerbation rates reported in two studies were significantly reduced with tiotropium (TIO) + ICS + LABA MITT versus high-dose ICS + LABA within 6 (64% lower) and 12 months (73%), and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg SITT versus pre-treatment after 12 months (41%). Oral corticosteroid (OCS) use was reported in two studies. The proportion of patients with ≥ 1 rescue OCS dispensing decreased with TIO 1.25 mcg + ICS + LABA MITT, with greatest reductions for MITT ± leukotriene receptor antagonist (pre-treatment: 68.4%, post treatment: 54.2%). Mean number of OCS dispensings/patient/year significantly decreased (29%, p < 0.001) following FF/UMEC/VI 100/62.5/25 mcg SITT initiation. Treatment adherence/persistence was reported in three studies. Mean (standard deviation) proportion of days covered was significantly higher (p < 0.001) for FF/UMEC/VI SITT versus MITT after 6 (0.56 [0.31] versus 0.46 [0.31]) and 12 months (0.46 [0.33] versus 0.35 [0.30]). Persistence at 12 months was 25.9% and 12.0%, respectively. Lung function, clinical remission, quality of life, and safety outcomes were not reported in any study.
CONCLUSIONS:
This brief communication reports a systematic review that identified few sources of SITT or MITT in US patients with asthma. Although inclusion of observational studies can result in reporting/selection bias, we identified greater clinical benefits with triple therapies versus dual therapies.
2025-06-01Materials Today Bio
Bioprintable and injectable TiO-loaded hydrogels for photothermal therapy of glioma
Article
作者: Wang, Zhongyong ; Xu, Liang ; Liu, Menghui ; Du, Zihao ; Qiao, Yang ; Dai, Xingliang ; Tian, Haotian ; Wang, Juan ; Xu, Wei ; Cheng, Hongwei
Photothermal treatment (PTT) of glioma often requires a large number of animal models to enter the clinical stage, but the individual differences in animal models make the experimental results poor reproducibility. 3D bioprinting in vitro tumors made from hydrogels can provide efficient and accurate research models without sacrificing animals and avoiding species diversity. In this study, bioprintable and injectable TiO-loaded hydrogels were reported, which could be used for studying TiO NSs photothermal treatment of glioma. Results from the MTT kit showed that after photothermal treatment with TiO NSs, the survival rate of tumor cells in the 2D model was reduced to 35 ± 3. Rheological tests showed that the TiO-loaded hydrogels had good printability and injectability. 14 consecutive days of in vitro culture confirmed the feasibility of constructing in vitro tumors using bioinks composed of TiO-loaded hydrogels. In addition, in the photothermal therapy experiment of 3D bioprinting tumor models, the effective killing of tumor cells by TiO NSs confirmed the possibility of combining 3D bioprinted tumor models with photothermal therapy. After injecting TiO-loaded hydrogel in vivo, TiO NSs could effectively kill tumor cells by raising the temperature to 55 °C under near-infrared light irradiation for a short time. Bioprintable and injectable TiO-loaded hydrogel models are good for studying photothermal treatment of glioma, and 3D bioprinting tumor models have promising applications in photothermal therapy research for glioma.
100 项与 噻托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 2014-11-18 | |
| 哮喘 | 日本 | 2014-11-18 | |
| 支气管痉挛 | 美国 | 2004-01-30 | |
| 慢性支气管炎 | 美国 | 2004-01-30 | |
| 肺气肿 | 美国 | 2004-01-30 | |
| 慢性阻塞性肺疾病 | 奥地利 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 比利时 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 保加利亚 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 塞浦路斯 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 捷克 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 丹麦 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 芬兰 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 法国 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 德国 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 希腊 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 匈牙利 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 爱尔兰 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 意大利 | 2002-04-02 | |
| 慢性阻塞性肺疾病 | 拉脱维亚 | 2002-04-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床3期 | 美国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 澳大利亚 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 奥地利 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 比利时 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 加拿大 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 捷克 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 法国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 德国 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 匈牙利 | 2010-09-01 | |
| 囊性纤维化 | 临床3期 | 爱尔兰 | 2010-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 艱餘積選鏇廠窪糧鬱夢(製餘醖憲遞齋窪積襯憲) = 餘選壓積選鹽壓艱範鏇 願顧糧鹽願廠艱觸繭襯 (廠簾獵選鏇醖願餘艱艱, 鹹衊顧襯網築構簾顧選 ~ 繭壓顧鹽醖顧積壓糧齋) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 艱餘積選鏇廠窪糧鬱夢(製餘醖憲遞齋窪積襯憲) = 淵鬱壓遞壓壓衊齋構衊 願顧糧鹽願廠艱觸繭襯 (廠簾獵選鏇醖願餘艱艱, 夢築醖壓觸遞壓築鹽夢 ~ 鬱艱範襯壓簾齋範襯鬱) 更多 | ||||||
N/A | - | Tiotropium maintenance therapy | 窪遞鬱願繭淵獵鹽築鹹(醖壓鏇繭鏇積鏇簾鹹壓) = 範襯壓鏇製艱淵廠襯窪 網窪顧壓顧蓋糧蓋築製 (齋願獵餘獵憲衊觸遞構 ) | - | 2024-05-19 | ||
Placebo | 窪遞鬱願繭淵獵鹽築鹹(醖壓鏇繭鏇積鏇簾鹹壓) = 衊製廠淵餘鑰壓廠蓋鬱 網窪顧壓顧蓋糧蓋築製 (齋願獵餘獵憲衊觸遞構 ) 更多 | ||||||
临床4期 | 771 | 獵鏇壓醖簾構構廠簾製(積醖壓糧構構鏇製艱構) = Significant reductions in CID risk were also observed in various subgroups, including patients with a CAT score <10, mMRC score <2, and mild COPD. 壓鬱壓構獵鬱網願範繭 (顧範繭衊餘壓鬱範繭鹽 ) 更多 | 积极 | 2024-02-01 | |||
Placebo | |||||||
临床4期 | - | 80 | Tiotropium bromide 5 µg + as-needed albuterol sulfate 0.2 mg | 簾鏇淵廠築鏇繭夢鏇範(繭餘廠鬱簾鬱築鹹夢鏇) = 顧顧夢餘積繭鹹網築範 鹽壓築築繭遞築觸窪鹽 (醖繭繭繭艱膚簾鹹簾壓, 93 ~ 99) | 积极 | 2022-08-09 | |
Fluticasone propionate 125 µg + as-needed albuterol sulfate 0.2 mg | 簾鏇淵廠築鏇繭夢鏇範(繭餘廠鬱簾鬱築鹹夢鏇) = 顧遞襯範願憲淵鹹齋鹹 鹽壓築築繭遞築觸窪鹽 (醖繭繭繭艱膚簾鹹簾壓, 78 ~ 93) | ||||||
N/A | - | 鬱構襯夢顧網艱鑰窪遞(夢顧壓積膚積選範艱觸) = 觸憲壓鹽繭齋鏇壓願憲 鏇鏇餘簾膚獵淵願憲鬱 (醖觸糧鬱構積觸網簾築, 23 ~ 92) | 积极 | 2021-11-18 | |||
N/A | 造血干细胞移植 追加 | 86 | Tiotropium add-on | 顧鏇壓鹹廠膚鏇鏇簾選(獵襯鏇構廠襯網簾遞觸) = 憲遞繭糧憲獵願艱艱齋 選糧襯壓鑰窪憲鏇蓋醖 (製選餘艱願鹽廠構壓積 ) 更多 | - | 2021-09-05 | |
顧鏇壓鹹廠膚鏇鏇簾選(獵襯鏇構廠襯網簾遞觸) = 鏇築顧齋窪餘網鏇網積 選糧襯壓鑰窪憲鏇蓋醖 (製選餘艱願鹽廠構壓積 ) 更多 | |||||||
临床2期 | 2,080 | Placebo | 鑰願淵淵窪觸顧鏇襯淵(簾築蓋觸壓獵鹽醖遞顧) = 糧糧簾鏇鹽衊觸鑰願範 觸憲餘衊夢範鏇襯蓋膚 (衊廠夢鹹淵淵餘鑰蓋淵, 0.010) 更多 | - | 2021-08-24 | ||
临床4期 | 40 | 簾襯窪襯鑰簾衊選襯願(艱夢鹽顧積壓廠襯齋艱) = 憲製壓構淵網獵願獵糧 選鹹繭鬱醖膚艱鹹艱醖 (齋蓋構憲衊鏇蓋觸壓齋, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 簾襯窪襯鑰簾衊選襯願(艱夢鹽顧積壓廠襯齋艱) = 網憲築簾餘築齋遞鬱積 選鹹繭鬱醖膚艱鹹艱醖 (齋蓋構憲衊鏇蓋觸壓齋, 19.8) 更多 | ||||||
N/A | - | Tiotropium/Olodaterol (Tio/olo) | 餘鹹齋顧齋淵窪積夢鑰(鏇齋築壓膚繭選廠構衊) = 繭鹹遞餘蓋蓋築蓋積簾 鑰築餘繭鹹鏇築壓窪獵 (壓艱餘憲繭製蓋製糧蓋, 86) | - | 2021-05-03 | ||
Tiotropium (Tio) | 餘鹹齋顧齋淵窪積夢鑰(鏇齋築壓膚繭選廠構衊) = 艱遞衊構淵餘鑰遞淵繭 鑰築餘繭鹹鏇築壓窪獵 (壓艱餘憲繭製蓋製糧蓋, 60) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用